Competition & Markets Authority
Imprivata and Isosec abandon merger during CMA investigation
Imprivata and Isosec have abandoned their proposed tie-up after the CMA found competition concerns.
Based on assurances received from Imprivata that the deal has been abandoned, the Competition and Markets Authority (CMA) has decided not to refer the merger for an in-depth investigation.
Imprivata and Isosec provide secure authentication management solutions to healthcare providers in England. These technologies can give staff protected access to sensitive patient data sourced from a central NHS IT system.
In its initial ‘Phase 1’ investigation, the CMA found evidence indicating that Imprivata and Isosec are important rivals in this area and that part of the motivation for the takeover was the removal of a competitive threat from the market. Competition between these companies was also expected to grow in the future with the introduction of new products.
The CMA was concerned that, if the merger went ahead as planned, it would have an impact on NHS and other healthcare providers across England and could potentially lead to taxpayers receiving poorer value for money in relation to these services. In addition, the companies’ customers, including the NHS, would have limited other options in terms of suppliers.
The CMA announced on 29 April 2021 it would refer the deal to an in-depth Phase 2 investigation unless the parties offered acceptable undertakings to address these competition concerns. As the transaction has been abandoned, the deal will now not be referred.
More information is available on the Imprivata, Inc./Isosec Limited merger inquiry page.
For media enquiries, contact the CMA press office on 020 3738 6460 or email@example.com.
Latest News from
Competition & Markets Authority
CMA issues IVF guidance on consumer rights11/06/2021 12:20:00
The CMA has published new guidance to make clear clinics’ legal obligations to treat people fairly and to help IVF patients understand their consumer rights.
CMA launches action against British Airways and Ryanair over refunds09/06/2021 13:20:00
The CMA is investigating whether British Airways and Ryanair have broken consumer law by failing to offer refunds for flights customers could not legally take.
Reassessment of FNZ/GBST deal confirms competition concerns07/06/2021 10:15:00
The CMA has found that the purchase of GBST by rival FNZ could lead to poorer service and higher prices following a careful reassessment of the deal.
CMA investigates Facebook’s use of ad data04/06/2021 13:05:00
The CMA is investigating whether Facebook might be abusing a dominant position in the social media or digital advertising markets through its collection and use of advertising data.
CMA consults on new internal market role28/05/2021 12:20:00
The CMA is inviting views on its proposals for how the newly created Office for the Internal Market (OIM) is expected to work.
Teletext to pay back over £7 million for all outstanding refunds26/05/2021 15:25:00
Teletext Holidays has given formal commitments to pay all outstanding refunds to customers for package holidays that it cancelled due to the COVID-19 pandemic.
CMA secures refund rights for McAfee customers26/05/2021 10:25:00
Following CMA action, McAfee, a leading supplier of anti-virus software, has extended its refund rights for all customers whose contracts have auto-renewed.
CMA welcomes Tribunal judgment in Sabre case24/05/2021 14:33:00
The CMA recently (21 May 2021) welcomed Competition Appeal Tribunal judgment, dismissing Sabre’s challenge of the CMA’s decision to block its proposed acquisition of Farelogix.